Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1022-1027

  Harada, Naoki ^a   Inoue, Kaoru ^a   Yamaji, Ryoichi ^a   Nakano, Yoshihisa ^b   Inui, Hiroshi ^a  

^a Osaka Prefecture University   (Japan)

^b Osaka Women's Junior College   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2AMINOETHYL)BENZENESULFONYL FLUORIDE; AMINO ACID; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROGEN RECEPTOR ANTIBODY; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BICALUTAMIDE; LIGAND; PROTEINASE INHIBITOR; RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOACCUMULATION; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOLECULAR RECOGNITION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LEUPEPTINS; MALE; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE PROTEINASE INHIBITORS; SULFONES; TOSYL COMPOUNDS;

EID: 84861691516     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02250.x     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61.
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
5. Pissios P, Tzameli I, Moore DD. New insights into receptor ligand binding domains from a novel assembly assay. J Steroid Biochem Mol Biol 2001; 76: 3-7.
6. Shen HC, Coetzee GA. The androgen receptor: unlocking the secrets of its unique transactivation domain. Vitam Horm 2005; 71: 301-19.
7. Gobinet J, Poujol N, Sultan Ch. Molecular action of androgens. Mol Cell Endocrinol 2002; 198: 15-24.
8. Jenster G, van der Korput HA, van Vroonhoven C et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991; 5: 1396-404.
9. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9.
10. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90.
11. Libertini SJ, Tepper CG, Rodriguez V et al. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007; 67: 9001-5.
12. Harada N, Yasunaga R, Higashimura Y et al. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells. J Biol Chem 2007; 282: 22651-61.
13. Culig Z, Hoffmann J, Erdel M et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81: 242-51.
14. Compagno D, Merle C, Morin A et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2007; 2: e1006.
15. Harada N, Ohmori Y, Yamaji R et al. ARA24/Ran enhances the androgen-dependent NH2- and COOH-terminal interaction of the androgen receptor. Biochem Biophys Res Commun 2008; 373: 373-7.
16. 2+ exchanger. Biochim Biophys Acta 2003; 1593: 269-76.
17. Sheflin L, Keegan B, Zhang W et al. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 2000; 276: 144-50.
18. Chandra S, Shao J, Li JX et al. A common motif targets huntingtin and the androgen receptor to the proteasome. J Biol Chem 2008; 283: 23950-5.
19. Jenster G, van der Korput HA, Trapman J et al. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995; 270: 7341-6.
20. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 2011; 68: 3971-81.
21. Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
22. Ford OH, Gregory CW, Kim D et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170: 1817-21.
23. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
24. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
25. Pan J, Zhang Q, Wang Y et al. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS ONE 2010; 5: e13298.
26. Furutani T, Watanabe T, Tanimoto K et al. Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun 2002; 294: 779-84.
27. Pissios P, Tzameli I, Kushner P et al. Dynamic stabilization of nuclear receptor ligandbinding domains by hormone or corepressor binding. Mol Cell 2000; 6: 245-53.
28. Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J Cell Sci 2003; 116: 585-6.
29. Sterz J, von Metzler I, Hahne JC et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008; 17: 879-95.
30. Lin HK, Altuwaijri S, Lin WJ et al. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002; 277: 36570-6.
31. Harada N, Murata Y, Yamaji R et al. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol 2007; 53: 556-60.
32. Harada N, Atarashi K, Murata Y et al. Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: implification of DNA binding and acetylation of the receptor. J Steroid Biochem Mol Biol 2011; 123: 65-70.
33. Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-46.